Korean J Pain.  2022 Jan;35(1):14-21. 10.3344/kjp.2022.35.1.14.

Steroid injections in pain management: influence on coronavirus disease 2019 vaccines

Affiliations
  • 1Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, which has been rampant since the end of 2019, has evidently affected pain management in clinical practice. Fortunately, a COVID-19 vaccination program is currently in progress worldwide. There is an ongoing discussion that pain management using steroid injections can decrease COVID-19 vaccine efficacy, although currently there is no direct evidence to support this statement. As such, the feeling of pain in patients is doubled in addition to the co-existing ill-effects of social isolation associated with the pandemic. Thus, in the COVID-19 era, it has become necessary that physicians be able to provide high quality pain management without negatively impacting COVID-19 vaccine efficacy. Steroids can alter the entire process involved in the generation of adaptive immunity after vaccination. The period of hypophysis-pituitary-adrenal axis suppression is known to be 1 to 4 weeks after steroid injection, and although the exact timing for peak efficacy of COVID-19 vaccines is slightly different for each vaccine, the average is approximately 2 weeks. It is suggested to avoid steroid injections for a total of 4 weeks (1 week before and after the two vaccine doses) for the doubleshot vaccines, and for 2 weeks in total (1 week before and after vaccination) for a single-shot vaccine. This review focuses on the basic concepts of the various COVID-19 vaccines, the effect of steroid injections on vaccine efficacy, and suggestions regarding an appropriate interval between the administration of steroid injections and the COVID-19 vaccine.

Keyword

Adaptive Immunity; Coronavirus; COVID-19; COVID-19 Vaccines; Immunization Programs; Immunosuppression; Injections; Nerve Block; Pain; Pain Management; Pandemics; Social Isolation; Steroids

Figure

  • Fig. 1 Suitable time interval between pain management using steroids and coronavirus disease 2019 (COVID-19) vaccination, before and after the vaccination. In a 2 shot vaccine (AstraZeneca AZD1222, Pfizer-BioNTech BNT162b2, Moderna mRNA-1273), it is desirable to avoid steroid injections for a total of 4 weeks (1 week before and after the two vaccine doses), and in a single shot vaccine (Johnson & Johnson Ad26.COV2.S), this duration is 2 weeks in total (1 week before and after vaccination).


Cited by  1 articles

Timing of musculoskeletal steroid injections in pain practice during Coronavirus disease 2019 (COVID-19) vaccine administration
Kyung-Hoon Kim
Korean J Pain. 2022;35(1):1-3.    doi: 10.3344/kjp.2022.35.1.1.


Reference

1. World Health Organization. 2021. WHO Corona virus (COVID-19) dashboard [Internet]. World Health Organization;Geneva: Available at: https://covid19.who.int/.
2. Ministry of Food and Drug Safety of Korea. 2021. Information of Corona virus (COVID-19) vaccines in Korea [Internet]. Ministry of Food and Drug Safety of Korea;Cheongju: Available at: https://www.mfds.go.kr/vaccine_covid19.jsp.
3. Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, et al. 2020; Vaccines for COVID-19. Clin Exp Immunol. 202:162–92. DOI: 10.1111/cei.13517. PMID: 32935331. PMCID: PMC7597597.
Article
4. Nagy A, Alhatlani B. 2021; An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 19:2508–17. DOI: 10.1016/j.csbj.2021.04.061. PMID: 33936564. PMCID: PMC8076774.
Article
5. Yoo JH. 2021; What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci. 36:e54. DOI: 10.3346/jkms.2021.36.e54. PMID: 33559409. PMCID: PMC7870421.
Article
6. Lipsitch M, Kahn R. 2021; Interpreting vaccine efficacy trial results for infection and transmission. Vaccine. 39:4082–8. DOI: 10.1016/j.vaccine.2021.06.011. PMID: 34130883. PMCID: PMC8197448.
Article
7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. 2020; Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 383:2603–15. DOI: 10.1056/NEJMoa2034577. PMID: 33301246. PMCID: PMC7745181.
Article
8. Lee H, Punt JA, Miller DC, Nagpal A, Smith CC, Sayeed Y, et al. 2021; Do corticosteroid injections for the treatment of pain influence the efficacy of mRNA COVID-19 vaccines? Pain Med. 22:994–1000. DOI: 10.1093/pm/pnab063. PMID: 33605425. PMCID: PMC7928682.
Article
9. Strehl C, Ehlers L, Gaber T, Buttgereit F. 2019; Glucocorticoids-all-rounders tackling the versatile players of the immune system. Front Immunol. 10:1744. DOI: 10.3389/fimmu.2019.01744. PMID: 31396235. PMCID: PMC6667663.
Article
10. Akondy RS, Fitch M, Edupuganti S, Yang S, Kissick HT, Li KW, et al. 2017; Origin and differentiation of human memory CD8 T cells after vaccination. Nature. 552:362–7. DOI: 10.1038/nature24633. PMID: 29236685. PMCID: PMC6037316.
Article
11. Lindgren G, Ols S, Liang F, Thompson EA, Lin A, Hellgren F, et al. 2017; Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol. 8:1539. DOI: 10.3389/fimmu.2017.01539. PMID: 29181005. PMCID: PMC5693886.
Article
12. Hartley GE, Edwards ESJ, Aui PM, Varese N, Stojanovic S, McMahon J, et al. 2020; Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 5:eabf8891. DOI: 10.1126/sciimmunol.abf8891. PMID: 33443036. PMCID: PMC7877496.
Article
13. Ingawale DK, Mandlik SK. 2020; New insights into the novel anti-inflammatory mode of action of glucocorticoids. Immunopharmacol Immunotoxicol. 42:59–73. DOI: 10.1080/08923973.2020.1728765. PMID: 32070175.
Article
14. Kubiet MA, Gonzalez-Rothi RJ, Cottey R, Bender BS. 1996; Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids. Chest. 110:367–70. DOI: 10.1378/chest.110.2.367. PMID: 8697835.
Article
15. Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R, et al. 1979; Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA. 242:53–6. DOI: 10.1001/jama.1979.03300010037025. PMID: 312949.
Article
16. Coutinho AE, Chapman KE. 2011; The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 335:2–13. DOI: 10.1016/j.mce.2010.04.005. PMID: 20398732. PMCID: PMC3047790.
Article
17. Kroger A, Bahta L, Hunter P. 2021. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP) [Internet]. Centers for Disease Control and Prevention;Atlanta (GA): Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.
18. Fischer L, Gerstel PF, Poncet A, Siegrist CA, Laffitte E, Gabay C, et al. 2015; Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study. Arthritis Res Ther. 17:151. DOI: 10.1186/s13075-015-0663-9. PMID: 26048579. PMCID: PMC4481118.
19. Yıldız N, Sever L, Kasapçopur Ö, Çullu F, Arısoy N, Çalışkan S. 2013; Hepatitis B virus vaccination in children with steroid sensitive nephrotic syndrome: immunogenicity and safety? Vaccine. 31:3309–12. DOI: 10.1016/j.vaccine.2013.05.004. PMID: 23684838.
Article
20. Hottinger AF, George AC, Bel M, Favet L, Combescure C, Meier S, et al. 2012; A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. Oncologist. 17:436–45. DOI: 10.1634/theoncologist.2011-0342. PMID: 22357731. PMCID: PMC3316930.
Article
21. Vormehr M, Lehar S, Kranz LM, Tahtinen S, Oei Y, Javinal V, et al. 2020; Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. Oncoimmunology. 9:1758004. DOI: 10.1080/2162402X.2020.1758004. PMID: 32923115. PMCID: PMC7458619.
Article
22. Stout A, Friedly J, Standaert CJ. 2019; Systemic absorption and side effects of locally injected glucocorticoids. PM R. 11:409–19. DOI: 10.1002/pmrj.12042. PMID: 30925034.
Article
23. Kang WY, Lee JW, Lee E, Kang Y, Ahn JM, Kang HS. 2019; Systemic effects of fluoroscopically guided epidural steroid injection with dexamethasone. Korean J Pain. 32:178–86. DOI: 10.3344/kjp.2019.32.3.178. PMID: 31257826. PMCID: PMC6615449.
Article
24. Chucair-Elliott AJ, Carr MM, Carr DJJ. 2017; Long-term consequences of topical dexamethasone treatment during acute corneal HSV-1 infection on the immune system. J Leukoc Biol. 101:1253–61. DOI: 10.1189/jlb.4A1116-459R. PMID: 28115476. PMCID: PMC5380376.
Article
25. Sytsma TT, Greenlund LK, Greenlund LS. 2018; Joint corticosteroid injection associated with increased influenza risk. Mayo Clin Proc Innov Qual Outcomes. 2:194–8. DOI: 10.1016/j.mayocpiqo.2018.01.005. PMID: 30225449. PMCID: PMC6124339.
Article
26. Habib GS. 2009; Systemic effects of intra-articular corticosteroids. Clin Rheumatol. 28:749–56. DOI: 10.1007/s10067-009-1135-x. PMID: 19252817.
Article
27. Miller DC, Patel J, Gill J, Mattie R, Saffarian M, Schneider BJ, et al. 2020; Corticosteroid injections and COVID-19 infection risk. Pain Med. 21:1703–6. DOI: 10.1093/pm/pnaa199. PMID: 32699893. PMCID: PMC7454880.
Article
28. Weitoft T, Rönnblom L. 2006; Glucocorticoid resorption and influence on the hypothalamic-pituitary-adrenal axis after intra-articular treatment of the knee in resting and mobile patients. Ann Rheum Dis. 65:955–7. DOI: 10.1136/ard.2005.041525. PMID: 16769782. PMCID: PMC1798213.
Article
29. Abdul AJ, Ghai B, Bansal D, Sachdeva N, Bhansali A, Dhatt SS. 2017; Hypothalamic pituitary adrenocortical axis suppression following a single epidural injection of methylprednisolone acetate. Pain Physician. 20:E991–1001. DOI: 10.36076/ppj/2017.7.E991. PMID: 29149147.
30. Iranmanesh A, Gullapalli D, Singh R, Veldhuis JD. 2017; Hypothalamo-pituitary-adrenal axis after a single epidural triamcinolone injection. Endocrine. 57:308–13. DOI: 10.1007/s12020-017-1357-7. PMID: 28674775. PMCID: PMC5554884.
Article
31. Brill S, Hochberg U, Goor-Aryeh I. 2021; Neuro-axial steroid injection in pain management and COVID-19 vaccine. Eur J Pain. 25:945–6. DOI: 10.1002/ejp.1749. PMID: 33565660. PMCID: PMC8013309.
Article
32. Chakravarthy K, Strand N, Frosch A, Sayed D, Narra LR, Chaturvedi R, et al. 2021; Recommendations and guidance for steroid injection therapy and COVID-19 vaccine administration from the American Society of Pain and Neuroscience (ASPN). J Pain Res. 14:623–9. DOI: 10.2147/JPR.S302115. PMID: 33716511. PMCID: PMC7944369.
Article
33. Friedly JL, Comstock BA, Heagerty PJ, Bauer Z, Rothman MS, Suri P, et al. 2018; Systemic effects of epidural steroid injections for spinal stenosis. Pain. 159:876–83. DOI: 10.1097/j.pain.0000000000001158. PMID: 29394207.
Article
34. Hasan SS, Capstick T, Zaidi STR, Kow CS, Merchant HA. 2020; Use of corticosteroids in asthma and COPD patients with or without COVID-19. Respir Med. 170:106045. DOI: 10.1016/j.rmed.2020.106045. PMID: 32843175. PMCID: PMC7255263.
Article
35. The Korean Pain Society. 2021. General guidelines for the management of patients with pain during the COVID-19 global pandemic era [Internet]. The Korean Pain Society;Seoul: Available at: http://www.painfree.or.kr/board/view.html?code=notify&num=10567.
36. Gharibo C, Sharma A, Soin A, Shah S, Diwan S, Buenaventura R, et al. 2020; Triaging interventional pain procedures during COVID-19 or related elective surgery restrictions: evidence-informed guidance from the American Society of Interventional Pain Physicians (ASIPP). Pain Physician. 23(4S):S183–204. DOI: 10.36076/ppj.2020/23/S183. PMID: 32942785.
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr